{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:59:00Z","timestamp":1780919940244,"version":"3.54.1"},"reference-count":49,"publisher":"Japan Atherosclerosis Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2023,8,1]]},"DOI":"10.5551\/jat.63404","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T22:23:53Z","timestamp":1665267833000},"page":"943-955","source":"Crossref","is-referenced-by-count":5,"title":["Long-Term Effectiveness of Cilostazol in Patients with Hemodialysis with Peripheral Artery Disease"],"prefix":"10.5551","volume":"30","author":[{"given":"Chung-Kuan","family":"Wu","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital"},{"name":"School of Medicine, Fu-Jen Catholic University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hsun","family":"Lin","sequence":"additional","affiliation":[{"name":"School of Medicine, Fu-Jen Catholic University"},{"name":"Division of Cardiovascular Surgery, Department of Surgery, Shin Kong Wu Ho-Su Memorial Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noi","family":"Yar","sequence":"additional","affiliation":[{"name":"College of Management, School of Health Care Administration, Taipei Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zih-Kai","family":"Kao","sequence":"additional","affiliation":[{"name":"Institute of Biophotonics, National Yang Ming Chiao Tung University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Bei","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Surgery, Department of Surgery, Shin Kong Wu Ho-Su Memorial Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Yi","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Hospital and Health Care Administration, National Yang Ming Chiao Tung University"},{"name":"Department of Research, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Morley RL, Sharma A, Horsch AD, Hinchliffe RJ. Peripheral artery disease. BMJ, 2018; 360: j5842","DOI":"10.1136\/bmj.j5842"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Farber A, Eberhardt RT. The current state of critical limb ischemia: a systematic review. JAMA Surg, 2016; 151: 1070-1077","DOI":"10.1001\/jamasurg.2016.2018"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Olinic DM, Spinu M, Olinic M, Homorodean C, Tataru DA, Liew A, Schernthaner GH, Stanek A, Fowkes G, Catalano M. Epidemiology of peripheral artery disease in Europe: VAS Educational Paper. Int Angiol, 2018; 37: 327-334","DOI":"10.23736\/S0392-9590.18.03996-2"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Virtanen J, Varpela M, Biancari F, Jalkanen J, Hakovirta H. Association between anatomical distribution of symptomatic peripheral artery disease and cerebrovascular disease. Vascular, 2020; 28: 295-300","DOI":"10.1177\/1708538119893825"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Agnelli G, Belch JJF, Baumgartner I, Giovas P, Hoffmann U. Morbidity and mortality associated with atherosclerotic peripheral artery disease: A systematic review. Atherosclerosis, 2020; 293: 94-100","DOI":"10.1016\/j.atherosclerosis.2019.09.012"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Bourrier M, Ferguson TW, Embil JM, Rigatto C, Komenda P, Tangri N. Peripheral artery disease: its adverse consequences with and without CKD. Am J Kidney Dis, 2020; 75: 705-712","DOI":"10.1053\/j.ajkd.2019.08.028"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Liew YP, Bartholomew JR, Demirjian S, Michaels J, Schreiber MJ. Combined effect of chronic kidney disease and peripheral arterial disease on all-cause mortality in a high-risk population. Clin J Am Soc Nephr, 2008; 3: 1084-1089","DOI":"10.2215\/CJN.04411007"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Rogers KC, Oliphant CS, Finks SW. Clinical efficacy and safety of cilostazol: a critical review of the literature. Drugs, 2015; 75: 377-395","DOI":"10.1007\/s40265-015-0364-3"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G. Cilostazol for intermittent claudication. Cochrane Database Syst Rev, 2014; 10: CD003748","DOI":"10.1002\/14651858.CD003748.pub4"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev, 2007; 1: CD003748","DOI":"10.1002\/14651858.CD003748.pub2"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) de Donato G, Setacci F, Mele M, Giannace G, Galzerano G, Setacci C. Restenosis after coronary and peripheral intervention: efficacy and clinical Impact of cilostazol. Ann Vasc Surg, 2017; 41: 300-307","DOI":"10.1016\/j.avsg.2016.08.050"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Nanto K, Iida O, Takahara M, Soga Y, Suzuki K, Hirano K, Kawasaki D, Shintani Y, Suematsu N, Yamaoka T, Uematsu M. Effect of cilostazol following endovascular intervention for peripheral artery disease. Angiology, 2015; 66: 774-778","DOI":"10.1177\/0003319714551361"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Megaly M, Abraham B, Saad M, Mekaiel A, Soukas P, Banerjee S, Shishehbor MH. Outcomes with cilostazol after endovascular therapy of peripheral artery disease. Vasc Med, 2019; 24: 313-323","DOI":"10.1177\/1358863X19838327"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Ishii H, Kumada Y, Toriyama T, Aoyama T, Takahashi H, Tanaka M, Kamoi D, Kawamura Y, Yamada S, Hayashi M, Yasuda Y, Yuzawa Y, Maruyama S, Matsuo S, Matsubara T, Murohara T. Effects of oral cilostazol 100 mg BID on long-term patency after percutaneous transluminal angioplasty in patients with femoropopliteal disease undergoing hemodialysis: a retrospective chart review in Japanese patients. Clin Ther, 2010; 32: 24-33","DOI":"10.1016\/j.clinthera.2010.01.007"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Ishii H, Kumada Y, Toriyama T, Aoyama T, Takahashi H, Yamada S, Yasuda Y, Yuzawa Y, Maruyama S, Matsuo S, Matsubara T, Murohara T. Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease. Clin J Am Soc Nephrol, 2008; 3: 1034-1040","DOI":"10.2215\/CJN.05761207"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Shiohira S, Yoshida T, Sugiura H, Yoshida S, Mitobe M, Shimada K, Ohba T, Tsuchiya K, Kabaya T, Nitta K. Effect of the antiplatelet agent cilostazol on endovascular inflammatory biochemical parameters and the clinical symptoms of peripheral artery disease and restless legs syndrome in hemodialysis patients. Clin Exp Nephrol, 2011; 15: 893-899","DOI":"10.1007\/s10157-011-0485-2"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Matsuda T, Sawada T, Yamaguchi T, Nishimaru K, Ohashi Y. Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis, 2000; 9: 147-157","DOI":"10.1053\/jscd.2000.7216"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C; CSPS 2 group. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol, 2010; 9: 959-968","DOI":"10.1016\/S1474-4422(10)70198-8"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Lee WH, Chu CY, Hsu PC, Su HM, Lin TH, Voon WC, Lai WT, Sheu SH. Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan. Thromb Res, 2013; 132: 190-195","DOI":"10.1016\/j.thromres.2013.01.036"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Lim PS, Jeng Y, Wu MY, Pai MA, Wu TK, Chen CH. Role of Cilostazol Therapy in hemodialysis patients with asymptomatic peripheral arterial disease: A retrospective cohort study. Biomed Res Int, 2016; 2016: 8236903","DOI":"10.1155\/2016\/8236903"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Ishii H, Aoyama T, Takahashi H, Kumada Y, Kamoi D, Sakakibara T, Umemoto N, Suzuki S, Tanaka A, Ito Y, Murohara T. Treatment with cilostazol improves clinical outcome after endovascular therapy in hemodialysis patients with peripheral artery disease. J Cardiol, 2016; 67: 199-204","DOI":"10.1016\/j.jjcc.2015.05.003"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Russell TE, Kasper GC, Seiwert AJ, Comerota AJ, Lurie F. Cilostazol may improve maturation rates and durability of vascular access for hemodialysis. Vasc Endovascular Surg, 2017; 51: 120-124","DOI":"10.1177\/1538574417692464"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) de Havenon A, Sheth KN, Madsen TE, Johnston KC, Turan TN, Toyoda K, Elm JJ, Wardlaw JM, Johnston SC, Williams OA, Shoamanesh A, Lansberg MG. Cilostazol for secondary stroke prevention: history, evidence, limitations, and possibilities. Stroke, 2021; 52: e635-e645","DOI":"10.1161\/STROKEAHA.121.035002"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Miller JB, Brauer E; Rao H, Wickenheiser K, Dev S, Omino R, Stokes-Buzzelli S. The most frequent ED patients carry insurance and a significant burden of disease. Am. J. Emerg. Med., 2013; 31: 16-19","DOI":"10.1016\/j.ajem.2012.05.001"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Morris JN, Howard EP, Steel K, Schreiber R, Fries BE, Lipsitz LA, Goldman B. Predicting risk of hospital and emergency department use for home care elderly persons through a secondary analysis of cross-national data. BMC Health Serv. Res., 2014; 14: 1-11","DOI":"10.1186\/s12913-014-0519-z"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Lin YC, Hsu HK, Lai TS, Chiang WC, Lin SL, Chen YM, Chen CC, Chu TS. Emergency department utilization and resuscitation rate among patients receiving maintenance hemodialysis. J Formos Med Assoc, 2019; 118: 1652-1660","DOI":"10.1016\/j.jfma.2019.01.007"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Ng\u2019andu NH. An empirical comparison of statistical tests for assessing the proportional hazards assumption of Cox\u2019s model. Stat Med, 1997; 16: 611-626","DOI":"10.1002\/(SICI)1097-0258(19970330)16:6<611::AID-SIM437>3.0.CO;2-T"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Hedeker, D., &amp; Leon, A. C. Propensity score stratification for observational comparison of repeated binary outcomes. Statistics and its Interface, 2011; 4: 489-498","DOI":"10.4310\/SII.2011.v4.n4.a7"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Garcia-Canton C, Rodenas A, Lopez-Aperador C, Rivero Y, Anton G, Monzon T, Diaz N, Vega N, Loro JF, Santana A, Esparza N. Frailty in hemodialysis and prediction of poor short-term outcome: mortality, hospitalization and visits to hospital emergency services. Ren Fail, 2019; 41: 567-575","DOI":"10.1080\/0886022X.2019.1628061"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Lin YC, Hsu HK, Lai TS, Chiang WC, Lin SL, Chen YM, Chen CC, Chu TS. Emergency department utilization and resuscitation rate among patients receiving maintenance hemodialysis. J Formos Med Assoc, 2019; 118: 1652-1660","DOI":"10.1016\/j.jfma.2019.01.007"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Hooker EA, Mallow PJ, Oglesby MM. Characteristics and trends of emergency department visits in the united states. J Emerg Med, 2019; 56: 344-351","DOI":"10.1016\/j.jemermed.2018.12.025"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Morcos R, Louka B, Tseng A, Misra S, McBane R, Esser H, Shamoun F. The evolving treatment of peripheral arterial disease through guideline-directed recommendations. J Clin Med, 2018; 7: 9","DOI":"10.3390\/jcm7010009"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Sachs T, Pomposelli F, Hamdan A, Wyers M, Schermerhorn M. Trends in the national outcomes and costs for claudication and limb threatening ischemia: angioplasty vs bypass graft. J Vasc Surg, 2011; 54: 1021-1031","DOI":"10.1016\/j.jvs.2011.03.281"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Mustapha JA, Anose BM, Martinsen BJ, Pliagas G, Ricotta J, Boyes CW, Lee MS, Saab F, Adams G. Lower extremity revascularization via endovascular and surgical approaches: A systematic review with emphasis on combined inflow and outflow revascularization. SAGE Open Med, 2020; 8: 2050312120929239","DOI":"10.1177\/2050312120929239"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Shiraki T, Iida O, Takahara M, Soga Y, Mii S, Okazaki J, Kuma S, Yamaoka T, Kamoi D, Shintani Y, Ishikawa T, Kitano I, Uematsu M. Comparison of clinical outcomes after surgical and endovascular revascularization in hemodialysis patients with critical limb ischemia. J Atheroscler Thromb, 2017; 24: 621-629","DOI":"10.5551\/jat.35915"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Okamoto S, Iida O, Mano T. Current perspective on hemodialysis patients with peripheral artery disease. Ann Vasc Dis, 2017; 10: 88-91","DOI":"10.3400\/avd.ra.17-00034"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Furuyama T, Onohara T, Yamashita S, Yoshiga R, Yoshiya K, Inoue K, Morisaki K, Kyuragi R, Matsumoto T, Maehara Y. Prognostic factors of ulcer healing and amputation-free survival in patients with critical limb ischemia. Vascular, 2018; 26: 626-633","DOI":"10.1177\/1708538118786864"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Neel JD, Kruse RL, Dombrovskiy VY, Vogel TR. Cilostazol and freedom from amputation after lower extremity revascularization. J Vasc Surg, 2015; 61: 960-964","DOI":"10.1016\/j.jvs.2014.11.067"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Niu PP, Guo ZN, Jin H, Xing YQ, Yang Y. Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. BMJ Open, 2016; 6: e009013","DOI":"10.1136\/bmjopen-2015-009013"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Xie W, Zheng F, Zhong B, Song X. Long-term antiplatelet mono- and dual therapies after ischemic stroke or transient ischemic attack: network meta-analysis. J Am Heart Assoc, 2015; 4: e002259","DOI":"10.1161\/JAHA.115.002259"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Wang W, Zhang L, Liu W, Zhu Q, Lan Q, Zhao J. Antiplatelet agents for the secondary prevention of ischemic stroke or transient ischemic attack: a network meta-analysis. J Stroke Cerebrovasc Dis, 2016; 25: 1081-1089","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.01.026"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Shi L, Pu J, Xu L, Malaguit J, Zhang J, Chen S. The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population--an updated meta-analysis. BMC Neurol, 2014; 14: 251","DOI":"10.1186\/s12883-014-0251-7"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Edrissi H, Schock SC, Cadonic R, Hakim AM, Thompson CS. Cilostazol reduces blood brain barrier dysfunction, white matter lesion formation and motor deficits following chronic cerebral hypoperfusion. Brain Res, 2016; 1646: 494-503","DOI":"10.1016\/j.brainres.2016.06.036"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Takagi T, Imai T, Mishiro K, Ishisaka M, Tsujimoto M, Ito H, Nagashima K, Matsukawa H, Tsuruma K, Shimazawa M, Yoshimura S, Kozawa O, Iwama T, Hara H. Cilostazol ameliorates collagenase-induced cerebral hemorrhage by protecting the blood-brain barrier. J Cereb Blood Flow Metab, 2017; 37: 123-139","DOI":"10.1177\/0271678X15621499"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Wu CK, Lin JW, Wu LC, Chang CH. Risk of heart failure hospitalization associated with cilostazol in diabetes: a nationwide case-crossover study. Front Pharmacol, 2019; 9: 1467","DOI":"10.3389\/fphar.2018.01467"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Ding XL, Xie C, Jiang B, Gao J, Zhang LL, Zhang H, Zhang JJ, Miao LY. Efficacy and safety of adjunctive cilostazol to dual antiplatelet therapy after stent implantation: an updated meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther, 2013; 18: 222-228","DOI":"10.1177\/1074248412468944"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Jang JS, Jin HY, Seo JS, Yang TH, Kim DK, Kim DS, Kim DK, Seol SH, Kim DI, Cho KI, Kim BH, Park YH, Je HG, Jeong YH, Kim WJ, Lee JY, Lee SW. A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation. Cardiology, 2012; 122: 133-143","DOI":"10.1159\/000339238"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Chen J, Meng H, Xu L, Liu J, Kong D, Chen P, Gong X, Bai J, Zou F, Yang Z, Li C, Eikelboom JW. Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. J Thromb Thrombolysis, 2015; 39: 23-24","DOI":"10.1007\/s11239-014-1090-5"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Bangalore S, Singh A, Toklu B, DiNicolantonio JJ, Croce K, Feit F, Bhatt DL. Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials. Open Heart, 2014; 1: e000068","DOI":"10.1136\/openhrt-2014-000068"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/30\/8\/30_63404\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:52:44Z","timestamp":1715575964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/30\/8\/30_63404\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.63404","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,1]]},"article-number":"63404"}}